The impact of Helicobacter pylori infection and eradication therapies on gut microbiota: a systematic review of microbial dysbiosis and its implications in gastric carcinogenesis
Abstract
Background: Helicobacter pylori is a globally prevalent bacterium associated with several gastrointestinal diseases, including peptic ulcers and gastric cancer. Growing interest has emerged in understanding how H. pylori affects gut microbiota and whether eradication therapies impact microbial balance, potentially influencing disease outcomes, including cancer progression.
Methods: A systematic review was conducted across PubMed, Scopus, and Web of Science databases using predefined keywords and Medical Subject Headings (MeSH) terms. Quality assessment was performed using the MINORS and Jadad scales.
Results: A total of 45 studies met the inclusion criteria, which evaluated microbial changes in H. pylori -infected individuals before and after eradication therapies. H. pylori infection resulted in significant alterations in gut and gastric microbiota, with a notable increase in inflammation-associated bacteria, such as Proteobacteria and Streptococcus. In gastric cancer patients, microbial diversity was reduced, with decreased levels of Bifidobacterium and Actinobacteria, and increased levels of Prevotella and Dialister, both associated with pro-inflammatory environments. Eradication therapies generally worsened dysbiosis initially, but probiotic supplementation promoted faster recovery of beneficial bacteria, improving microbial balance and reducing cancer-related dysbiosis.
Conclusion: H. pylori infection disrupts the gut microbiota, with eradication therapies further…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.